NEW YORK (GenomeWeb News) – BD Diagnostics said today that the US Food and Drug Administration has cleared the BD ProbeTec Trichomonas vaginalis Qx Amplified DNA Assay to run on BD's Viper System with XTR Technology.

The assay is for the qualitative detection of T. vaginalis DNA in endocervical and vaginal samples, as well as neat urine samples, to aid in the diagnosis of trichomoniasis. The assay is also CE-IVD marked.

BD Diagnostics, a segment of Becton Dickinson, today also launched the product.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.